Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00532883 · ClinicalTrials.gov registry record · Phase 2
Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease
A Phase 2 study, sponsored by St. Jude Children's Research Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00532883 is a Phase 2 study that was terminated before completion, run by St. Jude Children's Research Hospital. The registered enrollment target is 44 participants.
The verdict
NCT00532883, a Phase 2 study, was terminated before completion, sponsored by St. Jude Children's Research Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease that can cause intense pain episodes. Hemoglobin SCD (HbSC) is a form of SCD that is characterized by dense red blood cells. The purpose of this study is to evaluate the safety and effectiveness of hydroxyurea and magnesium pidolate, alone and combined, at reducing red blood cell density and the frequency of pain episodes in people with HbSC.
Interventions
- DRUG Hydroxyurea
- DRUG Magnesium Pidolate
- OTHER Placebo Pills and Placebo Liquid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00532883
The ClinicalTrials.gov registry entry for NCT00532883 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Hydroxyurea is the first listed.
NCT00532883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00532883 about?
NCT00532883 is a clinical study titled "Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease". Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease that can cause intense pain episodes. Hemoglobin SCD (HbSC) is a form of SCD that is characterized by dense red blood cells. The purpose of this study is to evaluate the safety and effectiveness of hydroxyurea...
What is the current status of trial NCT00532883?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2007-01. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00532883?
The interventions under investigation include: Hydroxyurea (DRUG), Magnesium Pidolate (DRUG), Placebo Pills and Placebo Liquid (OTHER).
Who is sponsoring clinical trial NCT00532883?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.